Different roles of PD-L1 and FasL in immunomodulation mediated by human placenta-derived mesenchymal stem cells

Human Immunology

Volumn 74, Issue 3, 2013, Pages 267-276

  Gu, Yan zheng ^a,b   Xue, Qun ^a,b   Chen, Yong jing ^b   Yu, Ge Hua ^b   Qing, Ming de ^b   Shen, Yu ^a   Wang, Ming yuan ^b,c   Shi, Qin ^a   Zhang, Xue Guang ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c Suzhou Red Cross Blood Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; INTERLEUKIN 10; NEUTRALIZING ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PLACENTA; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; MICROSCOPY, FLUORESCENCE; PHYTOHEMAGGLUTININS; PLACENTA; PREGNANCY; T-LYMPHOCYTES;

EID: 84873743220     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.12.011     Document Type: Article

References (40)

1. Fukuchi Y., Nakajima H., Sugiyama D., Hirose I., Kitamura T., Tsuji K. Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells 2004, 22:649-658.
2. Chien C.C., Yan B.L., Lee F.K., Lai T.H., Chen Y.C., Chan S.H., et al. In vitro differentiation of human placenta-derived multipotent cells into hepatocyte-like cells. Stem Cells 2006, 24:1759-1768.
3. Chang C.M., Kao C.L., Chang Y.L., Yang M.J., Chen Y.C., Sung B.L., et al. Placenta-derived multipotent stem cells induced to differentiate into insulin-positive cells. Biochem Biophys Res Commun 2007, 357:414-420.
4. Battula V.L., Bareiss P.M., Treml S., Conrad S., Albert I., Hojak S., et al. Human placenta and bone marrow derived MSC cultured in serum-free, b-FGF-containing medium express cell surface frizzled-9 and SSEA-4 and give rise to multilineage differentiation. Differentiation 2007, 75:279-291.
5. Barlow S., Brooke G., Chatterjee K., Price G., Pelekanos R., Rossetti T., et al. Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev 2008, 17:1095-1107.
6. Li C., Zhang W., Jiang X., Mao N. Human-placenta-derived masenchymal stem cells inhibit proliferation and function of allogeneic immune cells. Cell Tissue Res 2007, 330:437-446.
7. Chang C.J., Yen M.L., Chen Y.C., Chien C.C., Huang H.I., Bai C.H., et al. Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-γ. Stem Cells 2006, 24:2466-2477.
8. English K., Barry F.P., Field-Corbett C.P., Mahon B.P. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 2007, 110:91-100.
9. English K., Ryan J.M., Tobin L., Murphy M.J., Barry F.P., Mahon B.P. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4 +CD25(High) forkhead box P3 + regulatory T cells. Clin Exp Immunol 2009, 156:149-160.
10. Noel D., Djouad F., Bouffi C., Mrugala D., Jorgensen C. Multipotent mesenchymal stromal stem cells and immune tolerance. Leuk Lymphoma 2007, 48:1283-1289.
11. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
12. Sato K., Ozake K., Oh I., Meguro A., Hatanaka K., Nagai T., et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007, 109:228-234.
13. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
14. Maitra B., Szekely E., Gjini K., Laughlin M., Dennis J., Haynesworth S., et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T cell activation. Bone Marrow Transplant 2004, 33:597-604.
15. Zhang X., Schwartz J.C., Guo X., Bhatia S., Cao E., Lorenz M., et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immuity 2004, 20:337-347.
16. Sharpe A.H., Freeman G.J. The B7-CD28 superfamily. Nat Rev Immunol 2002, 2:116-126.
17. Yamazaki T., Akiba H., Koyanagi A., Azuma M., Yagita H., Okumura K. Blockade of B7-H1 on macrophages suppresses CD4+T Cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol 2005, 175:1586-1592.
18. Okazaki T., Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006, 27:175-201.
19. Brown J.A., Dorfman D.M., Ma F.R., Sullivan E.L., Munoz O., Wood C.R., et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cells activation and cytokine produciton. J Immunol 2003, 170:1257-1266.
20. Keir M.E., Francisco L.M., Sharpe A.H. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 2007, 19:309-314.
21. Gotsman I., Grabie N., Dacosta R., Sukhova G., Sharpe A., Lichtman A.H. Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. J Clin Invest 2007, 117:2974-2982.
22. Lee H.O., Ferquson T.A. Biology of FasL. Cytokine Growth Factor Rev 2003, 14:325-335.
23. Brunner T., Mogil R.J., LaFace D., Yoo N.J., Mahboubi A., Echeverri F., et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridoma. Nature 1995, 373:441-444.
24. Liu J., Lu X.F., Wan L., Li Y.P., Li S.F., Zeng L.Y., et al. Suppression of human peripheral blood lymphocyte proliferation by immortalized mesenchymal stem cells derived from bone marrow of Banna Minipig inbred-line. Transplant Proc 2004, 36:3272-3275.
25. Sun J., Xu K., Wu C., Wang Y., Hu Y., Zhu Y., et al. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens 2007, 69:19-27.
26. Xue Q., Luan X.Y., Gu Y.Z., Wu H.Y., Zhang G.-B., Yu G.H., et al. The negative co-signaling molecule B7-H4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity. Stem Cells Dev 2010, 19:27-38.
27. Pitenger M.F., Mackay A.M., Beck S.C., Jaiswai R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
28. Rao M.S., Mattson M.P. Stem cells and aging: expanding the possibilities. Mech Ageing Dev 2001, 122:713-734.
29. Krakowski M., Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 1996, 26:1641-1646.
30. Lee J., Zhuang Y., Wei X., Shang F., Wang J., Zhang Y., et al. Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis. J Mol Cell Cardiol 2009, 46:169-176.
31. Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res 2006, 312:2169-2179.
32. Gao K., Chen Y., Wei L., Li S., Jin X., Cong C., et al. Inhibitory effect of mesenchymal stem cells on lymphocyte proliferation. Cell Biochem Funct 2008, 26:900-907.
33. Augello A., Tasso R., Negrini S.M., Amateis A., Indiveri F., Cancedda R., et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of programmed death 1 pathway. Eur J immunol 2005, 35:1482-1490.
34. Fazekasova H., Lechler R., Langford K., Lombardi G. Placenta-derived MSCs are partially immunogenic and less immunomodulatory than bone marrow-derived MSCs. J Tissue Eng Regen Med 2011, 5:684.
35. Guleria I., Khosroshahi A., Ansari M.J., Habicht A., Azuma M., Yagita H., et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med 2005, 202:231-237.
36. Akiyama K., Chen C., Wang D.D., Xu X., Qu C., Yamaza T., et al. Mesenchymal-stem-cell-induced immunoregulation involves Fas-Ligand-/Fas- mediated T cell apoptosis. Cell Stem Cell 2012, 10:544.
37. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hssan M., Uzunel M., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cell. Lancet 2004, 363:1439-1441.
38. Sun L., Akiyama K., Zhang H., Yamaza T., Hou Y., Zhao S., et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009, 27:1421-1432.
39. Liang J., Zhang H., Hua B., Wang H., Wang J., Han Z., et al. Allogenetc mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult Scler 2009, 15:644.
40. Passweg J., Tyndall A. Autologous stem cell transplantation in autoimmune diseases. Semin Hematol 2007, 44:278-285.